ALOPM Stock Overview
A biopharmaceutical company, engages in the precision medicine business. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Oncodesign Precision Medicine Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.07 |
| 52 Week High | €2.27 |
| 52 Week Low | €0.92 |
| Beta | -0.70 |
| 11 Month Change | -10.83% |
| 3 Month Change | 0% |
| 1 Year Change | -51.58% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 25.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALOPM | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -0.9% | -7.1% | -2.1% |
| 1Y | -51.6% | -28.2% | -2.1% |
Return vs Industry: ALOPM underperformed the French Biotechs industry which returned -28.2% over the past year.
Return vs Market: ALOPM underperformed the French Market which returned -2.1% over the past year.
Price Volatility
| ALOPM volatility | |
|---|---|
| ALOPM Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALOPM's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALOPM's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 19 | Philippe Genne | www.oncodesign.com |
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s pipeline includes OPM-101, a potentially inhibitor of the RIPK2 target, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; OPM-102, a novel inhibitor that is in preclinical studies for the treatment of cancer; and OPM-201, a potential LRRK2 inhibitor, which is in Phase 1 clinical trial for the treatment of Parkinson’s disease. It is also developing drugs for the treatment of pancreatic and other cancers.
Oncodesign Precision Medicine Société anonyme Fundamentals Summary
| ALOPM fundamental statistics | |
|---|---|
| Market cap | €19.44m |
| Earnings (TTM) | -€7.79m |
| Revenue (TTM) | €1.34m |
14.5x
P/S Ratio-2.5x
P/E RatioIs ALOPM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALOPM income statement (TTM) | |
|---|---|
| Revenue | €1.34m |
| Cost of Revenue | €7.30m |
| Gross Profit | -€5.96m |
| Other Expenses | €1.83m |
| Earnings | -€7.79m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | -444.65% |
| Net Profit Margin | -581.49% |
| Debt/Equity Ratio | 239.2% |
How did ALOPM perform over the long term?
See historical performance and comparison